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Figure 1 - Mean (point), maximum (triangle) and minimum 
(square) value and standard deviation (line) of the difference 
between TG43 and TG186 results, for the dose points, 
bladder and rectum. 
 
Results: In all cases, the obtained dose following the TG186 
method was lower than that obtained with the TG43 
recommendations. Moreover, differences were found 
between the two described applicators (that had never been 
noticed with the TG43). The prescribed dose and the dose to 
2cc of the bladder and rectum varied as follows (figure 1): 
between 0.4% and 2.7% for the prescribed dose, between 
0.6% and 2.5% for the bladder and between 0.9% and 2.7% for 
the rectum. 
 
Conclusion: Differences were found between the dosimetry 
plans obtained with the TG43 and our model based dose 
calculation algorithm following TG186 recommendations. A 
deeper knowledge of this new algorithm and its applications 
in a more accurate dose calculation will be the future of this 
work. 
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Purpose or Objective: To assess the loco-regional efficacy 
and toxicity of a multimodal strategy including brachytherapy 
(BT) as part of the adjuvant treatment of localized high-
grade uterine sarcoma. 
 
Material and Methods: A single center retrospective analysis 
of patients (pts) treated from 1985 to 2015 was conducted. 
104 pts with high-grade uterine sarcoma were identified. 80 
pts had leiomyosarcomas, 17 undifferentiated sarcomas, 3 
rhabdomyosarcomas and 1 high grade adenosarcoma. 10 pts 
had a microscopic (n = 8) or macroscopic (n = 2) positive 
surgical margins. 
 
Results: The median follow-up time was 5.4 years. 57 pts 
underwent perioperative chemotherapy. 102 pts underwent 
postoperative external beam radiation therapy (EBRT) 
followed by a BT boost, and 2 pts received BT without EBRT. 
The median pelvic EBRT dose was 45 Gy (range 25-50.4). 69 
pts were treated with HDR BT (median dose = 10Gy), 33 with 
LDR (median dose = 15Gy), and 2 with PDR without EBRT 
(median dose = 60Gy). The 5-year local-regional failure-free 
survival and overall survival rates were 93% (CI 95% = 87-
99%), and 73%(CI 95% = 0.63-0.84%) respectively. Only 5 
vaginal recurrences were identified. 2 pts presented grade 3 
late toxicity, all other side effects were grade 2 or less. 
 
Conclusion: Adjuvant BT included in a multimodal treatment 
was associated with a high loco-regional control rate and 
acceptable acute and late toxicity in patient with localized 
high-grade uterine sarcoma. 
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Purpose or Objective: This study aims to demonstrate 
effective and non-invasive virtual pre-planning using week 5 
MRI without the need of applicator in-situ for image-guided 
cervix brachytherapy.  
 
Material and Methods: 15 patients with stage IB2-IVA 
cervical cancers were treated at our institution in January to 
October 2015 using chemoradiation and brachytherapy. All 
patients received whole pelvic radiotherapy 45Gy in 25 
fractions over 5 weeks, with concurrent weekly cisplatin 
40mg/m2 for up to 6 cycles, followed by additional 
parametrial boosting 10-16G in 5-8 fractions over 1-2 weeks. 
HDR brachytherapy using Ir-192 was performed in all patients 
at week 6 and 7, using Vienna schedule3 of 2 weekly 
insertions with 2 consecutive fractions per week, and first 
insertion was approximately 4-7 days after completion of 
whole pelvic radiotherapy. Treatment aim was 7Gy to HRCTV 
D90 each for 4 fractions. Week 5 MRI was performed in all 
patients, and HRCTVwk5 was contoured. Virtual preplanning 
was done with proposed applicators according to pre-
brachytherapy clinical assessment of dedicated oncologist. An 
estimated D90 for HRCTV (D90wk5) was then compared with 
the actual D90 HRCTV at week 6 and week 7. Maximum 
diameter for HRCTV at week 6 were measured, and plans 
with suboptimal coverage after brachytherapy was regarded 
as having cumulative D90 HRCTV </= 83.9Gy.  
 
Results: All 15 patients completed chemoradiation with 
schedule indicated. The choice of applicators was dependent 
on geometry of tumor (tandem and ovoids or ring or 
cylinder). Five patients were noted to have suboptimal tumor 
coverage, with cumulative D90 HRCTV dose ranging from 40.7 
to 70.7 Gy. The corresponding maximum diameter of week 6 
HRCTV was found to have significant correlation with 
cumulative HRCTV D90, and a cut-off value of tumor 
diameter 4.63cm could predict cumulative dose of 83.9 Gy. 
Based on the initial results, 2.5cm tumor radius from midline 
was decided to be the cut-off for using interstitial needles to 
improve dosimetry. With the implementation of interstital 
needles in September 2015, one patient received needle 
insertion based on virtual preplanning with estimated needle 
position and depth of insertion from week 5 MRI. Estimated 
HRCTV D90wk5 tumor radius from midline was 3.6cm. 
Improvement of HRCTV D90wk5 from 4.9Gy and 8.33 Gy was 
noted before and after virtual needle insertion. The 
subsequent week 6 and 7 brachytherapy using the 
preplanning information showed excellent correlation in 
terms of HRCTV D90 dosimetry, with cumulative HRCTVactual 
89.2Gy (dose per fraction was 7.8, 7.5, 8.6 and 8.6Gy 
respectively). 
 
Conclusion: This study demonstrates the effectiveness of a 
non-invasive method using week 5 MRI for virtual pre-
planning, with accurate estimation of HRCTV, that can guide 
needle insertion diligently. Tumor radius of 2.5cm was 
proven to be a good reference to select patients for 
interstitial needle insertion. 
 
 
 
 
